Cited by 442Gut microbiota and healthLiver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease

Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier

Open access
Zhou, Da, Pan, Qin, Xin, Feng-Zhi, Zhang, Rui-Nan, He, Chong-Xin, Chen, Guang-Yu, Liu, Chang, Chen, Yuan-Wen +1 more·2017·World Journal of Gastroenterology

Abstract

AIM: To investigate whether gut microbiota metabolite sodium butyrate (NaB) is an effective substance for attenuating non-alcoholic fatty liver disease (NAFLD) and the internal mechanisms. METHODS: Male C57BL/6J mice were divided into three groups, normal control were fed standard chow and model group were fed a high-fat diet (HFD) for 16 wk, the intervention group were fed HFD for 16 wk and treated with NaB for 8 wk. Gut microbiota from each group were detected at baseline and at 16 wk, liver histology were evaluated and gastrointestinal barrier indicator such as zonula occluden-1 (ZO-1) were detected by immunohistochemistry and realtime-PCR, further serum or liver endotoxin were determined by ELISA and inflammation- or metabolism-associated genes were quantified by real-time PCR. RESULTS: . These bacteria can produce butyric acid in what seems like a virtuous circle. And butyrate restored HFD induced intestinal mucosa damage, increased the expression of ZO-1 in small intestine, further decreased the levels of gut endotoxin in serum and liver compared with HF group. Endotoxin-associated genes such as TLR4 and Myd88, pro-inflammation genes such as MCP-1, TNF-α, IL-1, IL-2, IL-6 and IFN-γ in liver or epididymal fat were obviously downregulated after NaB intervention. Liver inflammation and fat accumulation were ameliorated, the levels of TG and cholesterol in liver were decreased after NaB intervention, NAS score was significantly decreased, metabolic indices such as FBG and HOMA-IR and liver function indicators ALT and AST were improved compared with HF group. CONCLUSION: NaB may restore the dysbiosis of gut microbiota to attenuate steatohepatitis, which is suggested to be a potential gut microbiota modulator and therapeutic substance for NAFLD.

Integrity signals

Registry

Crossref · 10.3748/wjg.v23.i1.60

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhou, D., Pan, Q., Xin, F.-Z., Zhang, R.-N., He, C.-X., Chen, G.-Y., Liu, C., Chen, Y.-W., & Fan, J.-G.
Affiliations
Shanghai Jiao Tong University (CN)
Venue
World Journal of Gastroenterology
Published
2017
Volume
23
Issue
1
Pages
60
ISSN
1007-9327 (ISSN-L)
OpenAlex
W2571212804
Cited by
441
References
56
Citations by year
2026: 34 · 2025: 61 · 2024: 66 · 2023: 58 · 2022: 68 · 2021: 46 · 2020: 50 · 2019: 30 · 2018: 17 · 2017: 11
FWCI
12.17
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
sodium butyrate, non-alcoholic fatty liver disease, steatohepatitis, high-fat diet, gut microbiota, intestinal barrier, zonula occludens-1, endotoxin, gut-liver axis, gut dysbiosis, inflammation, insulin resistance, butyrate
MeSH terms
Gastrointestinal Microbiome, Animals, Drug Evaluation, Preclinical, Humans, Immunohistochemistry, Inflammation, Intestinal Mucosa, Lactobacillus, Liver, Liver Function Tests, Male, Mice, Inbred C57BL, Specific Pathogen-Free Organisms, Tumor Necrosis Factor-alpha, Cytokines, Butyric Acid, Mice, Diet, High-Fat, Real-Time Polymerase Chain Reaction, Zonula Occludens-1 Protein, Dysbiosis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review